Rechallenge of ruxolitinib after momelotinib-related toxicity in a 74-yo woman with secondary myelofibrosis: a case report - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Reintroduction of ruxolitinib following toxicity from momelotinib in a 74-year-old female with secondary myelofibrosis: a case study

  • By

  • Jose Miguel Torregrosa Diaz

  • Laura Cailly

  • Maria Pilar Gallego Hernanz

  • Hélène Gardeney

  • Emilie Cayssials

  • July 1, 2026

Share

  • 1

    A 74-year-old female with secondary myelofibrosis was initially treated with high-dose ruxolitinib but switched to momelotinib due to transfusion-dependent anemia.

  • 2

    During treatment with momelotinib, the patient developed significant peripheral neuropathy and arthralgias, which were not managed effectively by dose reductions.

  • 3

    The patient was subsequently re-switched to low-dose ruxolitinib after improvement of anemia with momelotinib, leading to resolution of neuropathy.

  • 4

    This case is the first reported instance of ruxolitinib rechallenge following toxicity from momelotinib in a patient with myelofibrosis.

  • 5

    The experience highlights the potential for individualized JAK inhibitor sequencing and management of adverse effects in myelofibrosis treatment.

Original Source(s)

Rechallenge of ruxolitinib after momelotinib-related toxicity in a 74-yo woman with secondary myelofibrosis: a case report

  • by Jose Miguel Torregrosa Diaz, Laura Cailly, Maria Pilar Gallego Hernanz, Hélène Gardeney, Emilie Cayssials

  • July 1, 2026

Related Content

Establishment and clinical performance evaluation of the thyroglobulin colloidal gold immunochromatographic assay

Correction: Review and analysis of clinical trials of selective RET inhibitors for the treatment of thyroid cancer

Correction: Effect of bladder volume on dose of exposure to dangerous organs and incidence of cystitis and enteritis in patients with cervical cancer after external radiotherapy